HIV Drug Resistance: The 4th Decade

Assessment of Needs

The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians.

Antiretroviral therapy has dramatically reduced the morbidity and mortality associated with HIV infection. The emergence of drug resistance had limited the effectiveness of many initial drugs, however drug resistance is more uncommon with contemporary regimens such as those that include integrase strand transfer inhibitors. Despite the diminished impact clinically, drug resistance is one of the most frequently requested topics for discussion by our audience. This webinar will provide an up-to-date review on drug resistance and how resistance impacts clinical care.

Learning Objectives

On completion of this webinar, learners will be able to:

•  Appreciate that resistance to antiretroviral drugs has not been eliminated
• Describe the rates of drug resistance to antiretroviral drugs in currently recommended regimens in different geographic areas around the world
• Describe how archived resistance may hamper simplification of antiretroviral therapy (ART) [ie, 2-drug ART]
• Describe factors that may increase the potential for the emergence of resistance to 2nd generation integrase strand transfer inhibitors and long-acting drugs

Registration

Note: The IAS–USA acknowledges the importance of delivering the same high-quality education and resources to our audiences despite the challenging times we are experiencing due to the COVID-19 pandemic. In response, the implementation of a nominal fee to process the claim of CME and CE credits for webinars has been postponed.

Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, December 7, 2020, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Presenter

Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Roche (Updated 12/08/20)

Planner/Reviewer

Planner/Reviewer 1 has no relevant financial affiliations to disclose. (Updated 12/08/20)